Congress Wealth Management LLC DE decreased its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 15.7% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 121,889 shares of the company's stock after selling 22,721 shares during the quarter. Congress Wealth Management LLC DE's holdings in Johnson & Johnson were worth $17,628,000 at the end of the most recent quarter.
Other large investors also recently made changes to their positions in the company. Vinva Investment Management Ltd lifted its stake in shares of Johnson & Johnson by 6.8% during the 3rd quarter. Vinva Investment Management Ltd now owns 111,448 shares of the company's stock worth $17,988,000 after buying an additional 7,110 shares during the last quarter. Financial Counselors Inc. boosted its holdings in shares of Johnson & Johnson by 5.3% during the third quarter. Financial Counselors Inc. now owns 185,093 shares of the company's stock worth $29,996,000 after acquiring an additional 9,309 shares during the period. Oregon Pacific Wealth Management LLC bought a new position in shares of Johnson & Johnson during the fourth quarter worth approximately $949,000. Horan Securities Inc. lifted its holdings in Johnson & Johnson by 1.3% during the 4th quarter. Horan Securities Inc. now owns 7,178 shares of the company's stock worth $1,038,000 after purchasing an additional 90 shares during the last quarter. Finally, Strategic Financial Concepts LLC boosted its stake in Johnson & Johnson by 57.9% in the 4th quarter. Strategic Financial Concepts LLC now owns 3,467 shares of the company's stock valued at $501,000 after purchasing an additional 1,271 shares during the period. Institutional investors and hedge funds own 69.55% of the company's stock.
Analyst Ratings Changes
A number of brokerages have recently issued reports on JNJ. Barclays boosted their target price on shares of Johnson & Johnson from $159.00 to $166.00 and gave the company an "equal weight" rating in a research report on Tuesday, January 28th. Bank of America increased their target price on shares of Johnson & Johnson from $159.00 to $171.00 and gave the stock a "neutral" rating in a research report on Wednesday, March 5th. Wells Fargo & Company cut their price target on Johnson & Johnson from $166.00 to $152.00 and set an "equal weight" rating for the company in a research note on Thursday, January 23rd. Citigroup lowered their price objective on Johnson & Johnson from $185.00 to $175.00 and set a "buy" rating on the stock in a research note on Wednesday, December 11th. Finally, Stifel Nicolaus cut their target price on Johnson & Johnson from $170.00 to $155.00 and set a "hold" rating for the company in a research report on Thursday, January 23rd. Nine analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $171.33.
Get Our Latest Analysis on Johnson & Johnson
Johnson & Johnson Trading Down 1.3 %
NYSE JNJ traded down $2.15 during trading hours on Tuesday, reaching $161.14. The company's stock had a trading volume of 7,455,754 shares, compared to its average volume of 7,086,516. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $169.99. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.11 and a quick ratio of 0.86. The stock has a market cap of $388.32 billion, a P/E ratio of 24.23, a P/E/G ratio of 2.56 and a beta of 0.47. The firm has a fifty day simple moving average of $157.37 and a 200-day simple moving average of $156.16.
Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, topping analysts' consensus estimates of $1.99 by $0.05. The company had revenue of $22.52 billion for the quarter, compared to analyst estimates of $22.44 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. Johnson & Johnson's revenue was up 5.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.29 earnings per share. Equities analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.
Johnson & Johnson Announces Dividend
The business also recently disclosed a quarterly dividend, which was paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th were paid a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.08%. The ex-dividend date was Tuesday, February 18th. Johnson & Johnson's dividend payout ratio is currently 74.59%.
Insider Activity at Johnson & Johnson
In related news, EVP Timothy Schmid sold 403 shares of the company's stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total transaction of $62,928.45. Following the sale, the executive vice president now owns 15,098 shares in the company, valued at $2,357,552.70. This represents a 2.60 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Robert J. Decker sold 6,999 shares of Johnson & Johnson stock in a transaction that occurred on Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total value of $1,160,994.12. Following the completion of the sale, the vice president now owns 21,001 shares of the company's stock, valued at approximately $3,483,645.88. The trade was a 25.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by company insiders.
About Johnson & Johnson
(
Free Report)
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
Further Reading
Before you consider Johnson & Johnson, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson & Johnson wasn't on the list.
While Johnson & Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
